01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.10
−4.77%Margins
Gross margin
47.2%
EBITDA margin
-6.2%
EBIT margin
-13.2%
Net margin
-13.4%
FCF margin
-38.6%
-3.4%
Return on equity
-3.0%
Return on assets
-3.1%
Return on invested capital
0.23x
Asset turnover
-HKD 123.1M
Cash from operations
HKD 0.38
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026